Treatment with the probiotic Vivomixx appeared to lead to healthful changes in the gut microbiome of cystic fibrosis (CF) patients in a small clinical trial, including six with CF-related…
Last updated Aug. 5, 2025 by Agata Boxe
Fact-checked by Patrícia Silva, PhD
Although researchers have made significant progress with therapies for cystic fibrosis (CF), many aspects of the disease remain challenging to treat. Among them are worsening lung function and persistent lung infections, as well as other symptoms that affect daily life.
Scientists have been trying to address these issues through clinical trials, which test new therapies in people before they can be approved by the U.S. Food and Drug Administration (FDA) or regulatory agencies in other countries.
Joining a CF clinical trial can give you access to experimental treatments that may work for you while also helping researchers better understand CF.
However, if you’re considering joining a CF clinical trial, be sure to talk to your doctors first to determine whether it’s a safe and appropriate option for you.
Clinical trials for CF are research studies that examine new methods for treating, managing, or diagnosing CF. They’re usually done after lab and animal testing, helping scientists understand whether a CF therapy is safe and effective.
Clinical trials for CF can focus on:
There are different phases of CF clinical trials:
The progressive nature of CF may play a role in why someone would be open to accepting the risks involved in trials. Still, it is essential to carefully weigh those risks and benefits before considering potentially participating in one.
The benefits of CF clinical trials include:
The risks of CF clinical trials include:
There are several types of CF clinical trials, each with a different focus. They can explore a range of treatment goals, such as:
Some CF trials enroll people with specific genetic mutations, while others may target those who haven’t responded to existing CF therapies. Other trials may have different goals.
To learn more about ongoing or new clinical trials in cystic fibrosis, first speak with your CF doctors. Members of your healthcare team may be aware of trials through hospitals, research centers, or national networks. They can let you know if you may be a good candidate.
Publicly accessible websites and databases can also provide additional information.
For trials in the United States, you can consult these sources:
Sources for trial opportunities outside the U.S. include:
Asking questions can help you decide whether or not to participate in a trial. You may find it helpful to know exactly what to ask your CF doctor, the research team, and yourself as you are exploring the process.
Your doctor can answer general questions about CF trials, such as:
More detailed questions can be asked of researchers running the trial:
Asking about potential costs is especially important. Although most trials tend to cover the costs of the experimental treatment and any related medical care, that may not be the case for every single study.
If you are insured, you might want to ask your insurer whether or not the company can pay for your participation in the study, as well as care for potential side effects.
Participating in a clinical trial is a personal decision that should be made with careful consideration.
These self-reflective questions may help you make a decision:
CF clinical trials can provide a chance to try experimental treatments and give you more of a voice in your CF care. However, it is essential to keep in mind that these studies are not suitable for everyone, so it’s important to take the time to understand their risks and benefits.
Prioritize talking to your CF doctors first, so they can help you decide whether a CF trial is an option for you. And don’t hesitate to ask questions and advocate for yourself as you make this and other key decisions about your health and future.
Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Treatment with the probiotic Vivomixx appeared to lead to healthful changes in the gut microbiome of cystic fibrosis (CF) patients in a small clinical trial, including six with CF-related…
For people with cystic fibrosis (CF) who are not eligible for treatment with a CFTR modulator, seeing other patients benefit from these new therapies is “both uplifting and disheartening,” according to a new study. “Although most are happy for those who are benefiting from modulators, they are eager…
Six months of treatment with Trikafta does not substantially alter digestive symptoms in people with cystic fibrosis (CF), new research shows. “We speculate that [Trikafta], while it may lead to improvement in lung function, may have little or very delayed impact on gastrointestinal symptoms in people with CF,” Sarah…
A Phase 1/2 clinical trial of an aerosol gene therapy candidate, 4D-710, in people with cystic fibrosis (CF) has been cleared by U.S. Food and Drug Administration (FDA) and is expected to start this year, its developer, 4D Molecular Therapeutics, announced. The trial is designed as an open-label, dose-escalation…
A research ethics committee in Australia has given Krystal Biotech the go-ahead to start a Phase 1 clinical study of KB407, the company’s investigational inhaled gene therapy for cystic fibrosis (CF). Enrollment for the trial is expected to start soon, according to Krystal, following approval from the…

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.